Editorial: Metabolic reprogramming in breast cancer.

Autor: Scatena C; Division of Pathology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.; Department of Laboratory Medicine, Pisa University Hospital, Anatomia Patologica 1 Universitaria, Pisa, Italy., Naccarato AG; Division of Pathology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.; Department of Laboratory Medicine, Pisa University Hospital, Anatomia Patologica 1 Universitaria, Pisa, Italy., Ozsvari B; Translational Medicine, School of Science, Engineering and the Environment (SEE), University of Salford, Greater Manchester, United Kingdom., Scumaci D; Research Center on Advanced Biochemistry and Molecular Biology, Department of Experimental and Clinical Medicine, Magna Græcia University of Catanzaro, Catanzaro, Italy.
Jazyk: angličtina
Zdroj: Frontiers in oncology [Front Oncol] 2022 Nov 10; Vol. 12, pp. 1081171. Date of Electronic Publication: 2022 Nov 10 (Print Publication: 2022).
DOI: 10.3389/fonc.2022.1081171
Abstrakt: Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Databáze: MEDLINE